* Q4 loss/shr of $0.08 vs est of loss of $0.11
* Sees 2009 revenue of $148 mln to $160 mln
* Expects to realize majority of annual loss in H1 ‘09
Feb 3 (Reuters) - Genomic Health Inc (GHDX.O) posted a narrower-than-expected quarterly loss, helped by a 60 percent jump in sales of its breast cancer test.
The company said it expects to realize the majority of its expected annual loss in the first half of the year as it invests in its product pipeline, U.S. sales force expansion and worldwide commercial infrastructure.
For the full year ending Dec. 31, 2009, the company sees net loss of $7 million to $14 million.
For the fourth quarter, the company posted a net loss of $2.3 million, or 8 cents a share, compared with a loss of $6 million, or 21 cents a share, in the year-ago quarter.
Sales of its Oncotype DX breast cancer assay jumped 60 percent to $30.9 million.
Shares of Genomic Health were trading at $21.38 after the bell. They closed at $21.52 Tuesday on Nasdaq. (Reporting by Jennifer Robin Raj in Bangalore; Editing by Deepak Kannan)